Related Experiment Video
Updated: Oct 3, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
A Clinical Update on Vasoactive Medication in the Management of Cardiogenic Shock
Aditi Shankar1, Gayathri Gurumurthy2, Lakshmi Sridharan3
1Department of Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA.
Abstract:
This is a focused review looking at the pharmacological support in cardiogenic shock. There are a plethora of data evaluating vasopressors and inotropes in septic shock, but the data are limited for cardiogenic shock. This review article describes in detail the pathophysiology of cardiogenic shock, the mechanism of action of different vasopressors and inotropes emphasizing their indications and potential side effects. This review article incorporates the currently used specific risk-prediction models in cardiogenic shock as well as integrates data from many trials on the use of vasopressors and inotropes. Lastly, this review seeks to discuss the future direction for vasoactive medications in cardiogenic shock.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inotropic Agents

